PANS: A Treatable Condition with a Cure in Reach
PANS (Pediatric Acute-onset Neuropsychiatric Syndrome) is a childhood condition that can be triggered by various infections, including strep throat, the flu, chickenpox, mycoplasma, and Lyme disease…
Read the full articleYou might also wanna read
Crianças curadas da leucemia podem precisar tomar todas as vacinas novamente; estudo explica por quê
Estudo brasileiro publicado em revista científica internacional mostra que a quimioterapia pode comprometer a memória imunológica, deixando
Obsessive-Compulsive and Related Disorders in Children and Young People: Current Evidence and Clinical Approaches
Obsessive-Compulsive and Related Disorders in Children and Young People: Current Evidence and Clinical Approaches Short summary Obsessive-Co
Obsessive-Compulsive and Related Disorders in Children and Young People: Current Evidence and Clinical Approaches
Obsessive-Compulsive and Related Disorders in Children and Young People: Current Evidence and Clinical Approaches Short summary Obsessive-Co
New insights on polyomaviruses could inform future approaches to prevention, treatment
New insights on polyomaviruses could inform future approaches to prevention, treatment [email protected] July 6, 2026 PROVIDENCE, R.I. [Brown
ME/CFS Diagnosis and Management in Children and Adolescents: A Clinical Primer
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease that affects children and adolescents as well as adults. Th
pubmed.ncbi.nlm.nih.gov·1mo ago
FDA and CDC Investigate Multistate Infant Botulism Outbreak Linked to Nara Organics Powdered Infant Formula
The FDA and CDC, in collaboration with California Department of Public Health (CDPH), Infant Botulism Treatment and Prevention Program (IBTP
fda.gov·26d ago
Hausse des noyades infantiles : pourquoi les cours de natation dès 1 an sont cruciaux selon les pédiatres
Rapide et silencieuse, la noyade reste l'une des premières causes de décès des jeunes enfants. Dans la revue Pediatrics, des pédiatres rappe
Comments
Sign in to join the conversation.
No comments yet. Be the first.